Latest Industry Insights

This Q&A with researchers from the Buck Institute and Nautilus Biotechnology reveals how single-molecule proteomics enables unprecedented mapping of tau proteoforms across Alzheimer’s-relevant brain regions.

By harnessing advances in imaging technology and precision medicine, Serenatis Bio is hoping to transform the landscape of OCD treatments by targeting the root neurological causes of the disorder.

Dr. Najat Khan of Recursion shared insights into the creation of the Microglia Map and what it could mean for future drug discovery.

Explore the unique issues of rare disease trials and how “gene silencing” therapies could reshape the future for patients with H-ABC.

In this interview, Technology Networks spoke with Gene Mack, chief executive officer and president of Gain Therapeutics, to find out more about the company’s mission, its science and its vision for the future of neuroscience drug development.

In this interview, Felix Spira, senior manager at Molecular Devices, discusses how automation and AI improve brain organoid cultivation, enabling consistent long-term models that advance research into complex neurodegenerative diseases.

In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.

Technology Networks spoke with Nautilus Biotechnology and the Allen Institute about their new agreement to advance Alzheimer’s research through proteoform analysis.

This article explores the unique characteristics and challenges of life sciences marketing, offering insights on how to achieve meaningful engagement with a highly specialized audience.

Technology Networks recently spoke with Cristiano Tunesi to learn more about how cerebrospinal fluid biomarkers are transforming Alzheimer’s diagnosis, offering earlier and more accurate detection to guide treatment and improve outcomes.